DLBS2411 Treatment For Functional Dyspepsia

Status Recruiting

Clinical Trial Summary

This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit. The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. The mechanism altogether demonstrated DLBS2411's protective capacity to the gastric and colon mucosa by promoting mucous synthesis and stimulating mucosal blood flow. Having such mechanisms of action, DLBS2411 is hypothesized to benefit subjects with gastric acid disorders such as in functional dyspepsia, gastro-intestinal reflux disease (GERD), peptic-ulcer, and irritable bowel syndrome (IBS).

Clinical Trial Description

Study population will be patients with functional dyspepsia (FD) who come to the study site. There will be 100 subjects (50 subjects in each group) planned to be enrolled in the study. There will be 2 groups of treatment; Treatment 1: placebo DLBS2411 caplet Treatment 2: DLBS2411 250 mg caplet Each study medication will be administered 1 caplet twice daily, 30 minutes before meal, in the morning and evening. Eligible subjects will be randomly allocated to receive either Treatment 1 or Treatment 2 for 4 weeks, in a double blind fashion. Subjects will be instructed to come to the clinic every 2-week interval throughout the 4-week study period (at Week 2, and 4, respectively) and 8 weeks after the end of therapy (Week 12), for efficacy evaluation. The safety evaluation will be performed at Baseline and End of therapy (Week 4). Adverse events will be monitored at baseline and every follow-up visit including End of study (Week 12). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05248802
Study type	Interventional
Source	Dexa Medica Group
Contact	Ari F Syam, Prof, MD, Sp.PD-KGEH
Phone	+62818706199
Email	ari_syam@hotmail.com
Status	Recruiting
Phase	Phase 3
Start date	December 9, 2022
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04656730` - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas	Phase 4
Completed	`NCT04464369` - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial	Phase 4
Completed	`NCT01671670` - Acupuncture for Patients With Function Dyspepsia	Phase 2/Phase 3
Completed	`NCT00987805` - Efficacy of Banhasasim-tang on Functional Dyspepsia	Phase 4
Completed	`NCT00693407` - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation	N/A
Completed	`NCT00761358` - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia	Phase 3
Recruiting	`NCT01240096` - Mirtazapine Versus Placebo in Functional Dyspepsia	Phase 4
Recruiting	`NCT04540549` - Effects of Exercise on Functional Dyspepsia Based on Rome IV	N/A
Recruiting	`NCT03652571` - Nortriptyline for the Treatment of Functional Dyspepsia	Phase 3
Recruiting	`NCT06068114` - Gastric Pathophysiology in Diabetes
Recruiting	`NCT03825692` - International Clinical Study of Zhizhu Kuanzhong Capsule	Phase 4
Not yet recruiting	`NCT04548011` - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia	N/A
Terminated	`NCT02567578` - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia	Phase 2
Completed	`NCT03007433` - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging	N/A
Active, not recruiting	`NCT00990405` - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia	Phase 4
Completed	`NCT00404534` - Helicobacter Eradication Relief of Dyspeptic Symptoms	Phase 3
Completed	`NCT03043625` - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia	N/A
Completed	`NCT03225248` - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia	Phase 3
Recruiting	`NCT05587127` - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia	N/A
Recruiting	`NCT01021475` - Does Visceral Manipulation Works in Treating Functional Dyspepsia?	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.